about
Ischemia reperfusion dysfunction changes model-estimated kinetics of myofilament interaction due to inotropic drugs in isolated hearts.Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardiumThe therapeutic potential of novel cardiotonic agents.Levosimendan restores the positive force-frequency relation in heart failure.A novel steroid-like compound F90927 exerting positive-inotropic effects in cardiac muscle.Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.A Na+ channel agonist: a potential cardiotonic agent with a novel mechanism?Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.Insights into restrictive cardiomyopathy from clinical and animal studies.An emerging role for calcium sensitisation in the treatment of heart failure.Acute heart failure: inotropic agents and their clinical uses.Pharmacology of myocardial calcium-handling.Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.The myosin activator omecamtiv mecarbil: a promising new inotropic agent.Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?Does levosimendan act as Ca(2+) sensitizer or PDE3 inhibitor?Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure.Ischemia-reperfusion injury changes the dynamics of Ca2+-contraction coupling due to inotropic drugs in isolated hearts.Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.
P2860
Q34521831-C029B8D4-6B14-4423-AAC3-E456B2915B21Q35049090-4D9805FD-6E89-4064-960B-80FEADE97B15Q35117055-F401CC22-8658-41D4-8DB9-5E6808BC795CQ35159849-05667C75-4036-41EF-88A3-7A1170F89333Q35545792-5811956C-D3B7-48AC-87B4-55F1CE18F060Q35828900-3D339902-E3D6-4D07-808D-549CB47FE3F8Q35921814-A5EA9908-D9E8-4927-B27E-D2C8CB7B9683Q36048967-79EF9752-0204-4B9C-9A51-92CFBC56A4E2Q36077266-A4B45A99-BF4D-4828-98B3-6B19A328D319Q36187050-73E20CE5-2083-4D89-8B7B-43681252C618Q36632217-2AA62027-5AF8-4D11-B569-AE842BCE4DC7Q38019446-90EE658C-72D8-4197-9D6D-10BF09940D0FQ38644872-E76A3309-317E-4E62-91C8-B4544BAF5857Q38870685-B37D15F4-B2F1-44FC-93E2-CA607353898EQ41584608-B43E75E4-3B1E-4682-86AF-BA00D375E015Q42607945-AFD29E72-C784-441A-AE89-753F16662620Q45108007-34C481FB-9CB2-42E5-8EA8-1A66F1467A9FQ46638983-7942DB9E-9134-4740-AE10-ED1AE09E3E9DQ47237484-DA05B404-F412-4561-915C-4A30F5B26969
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mechanisms of action of novel cardiotonic agents.
@ast
Mechanisms of action of novel cardiotonic agents.
@en
Mechanisms of action of novel cardiotonic agents.
@nl
type
label
Mechanisms of action of novel cardiotonic agents.
@ast
Mechanisms of action of novel cardiotonic agents.
@en
Mechanisms of action of novel cardiotonic agents.
@nl
prefLabel
Mechanisms of action of novel cardiotonic agents.
@ast
Mechanisms of action of novel cardiotonic agents.
@en
Mechanisms of action of novel cardiotonic agents.
@nl
P1476
Mechanisms of action of novel cardiotonic agents.
@en
P2093
Masao Endoh
P304
P356
10.1097/00005344-200209000-00001
P407
P577
2002-09-01T00:00:00Z